Puberty blocker: drug companies’ shares fall after landmark transgender case The companies behind controversial puberty blockers at the centre of a landmark transgender ruling have seen their share prices dip. en staff The firms, AbbVie Inc and Takeda, saw the value of their shares fall in the aftermath of the Kiera Bell case. subscribe now Join today to gain access to the rest of this article and many others. more info login If you are already a subscriber, log in to continue. log in access code If you have an access code, enter it here: Go free trial Get free access for 14 days: Sign up Click here to find out how we take care of your personal data.